Zusammenfassung
Hypoglykämien sind häufige und potenziell lebensbedrohliche Nebenwirkungen einer inadäquaten Diabetestherapie. Das gilt besonders für schwere Hypoglykämien bei Typ-2-Diabetes. Kardiale Komplikationen sind Ischämien mit Major-Ereignissen, Herzrhythmusstörungen und Herzinsuffizienz. Ältere, multimorbide Patienten mit Typ-2-Diabetes und Polypharmazie oder/und autonomer kardialer Neuropathie markieren eine „very high risk group“. Die Glykämiekontrollziele sind an das Hypoglykämierisiko anzupassen. Priorität hat eine stabile Glukosehomeostase ohne Hypoglykämien und rasche Blutzuckerschwankungen. Ältere Typ-2-Diabetiker haben eine um mehr als 20% höhere Prävalenz von Vorhofflimmern. Bei Blutzuckerwerten unter 3 mmol/l und einer Dauer über 30 min treten QT-Zeit-Verlängerungen und ventrikuläre Tachykardien auf mit erhöhtem Risiko für Kammerflimmern und plötzlichen Herztod. Diese Herzrhythmusstörungen erhöhen bei Diabetikern mit Herzinsuffizienz signifikant die Mortalität. Rasche Blutzuckerschwankungen (MAGE >5 mmol/l) erhöhen die Vulnerabilität des elektrischen Systems des Herzrhythmus. Besonders gefährdet sind ältere, polymorbide Typ-2-Diabetiker mit vorbestehender Koronarerkrankung und kardialer autonomer Neuropathie. Antihyperglykämische, orale Antidiabetika (Metformin, Acarbose, SGLT-2-Inhibitoren), DPPIV-Inhibitoren und GLP-1-Analoga haben ein niedrigeres Hypoglykämierisiko im Vergleich zu Sulfonylharnstoffen und Insulin. Rechtzeitige Insulintherapie mit Basalinsulin bei unzureichendem Effekt von Metformin ist effektiv, sicher und einfach. Die Glykämieziele und Antidiabetika sind individualisiert nach dem Risiko-Nutzen-Profil auszuwählen. Dabei kommt dem Hypoglykämierisiko eine oft unterschätzte Bedeutung zu.
Abstract
Hypoglycemia is a common and potentially life-threatening adverse effect of inappropriate diabetes treatment. Typical cardiac complications are ischemia with angina pectoris, myocardial infarction, stroke and arrhythmias, such as atrial fibrillation (AF), ventricular tachycardia and heart failure. Elderly multimorbid patients with type 2 diabetes and polypharmacy and/or cardiac autonomous neuropathy represent a very high risk group for cardiovascular complications associated with hypoglycemia. Targets for glycemic control have to be adapted to the risk of hypoglycemia with a priority of stable glucose homeostasis without rapid fluctuations. Elderly patients with diabetes have a >20% risk of AF. At blood glucose levels of <3 mmol/l with a duration of >30 min, prolongation of QTc time and ventricular tachycardia occur with an increased risk of ventricular fibrillation and sudden death. Ventricular arrhythmias and AF significantly increase mortality in patients with heart failure. Rapid fluctuations with a mean amplitude of glucose excursion (MAGE) >5 mmol/l promote vulnerability of electrical stability of the heart, particularly in frail patients with preexisting coronary heart disease and autonomic neuropathy. Antihyperglycemic agents, such as metformin, acarbose and sodium glucose cotransporter 2 (SGLT2) inhibitors have only a low risk of severe hypoglycemia. Dipeptidyl peptase 4 (DPP-IV) inhibitors and glucagon-like peptide 1 (GLP1) analogues as insulin secretagogues have a lower risk for hypoglycemia than sulfonylurea and insulin. Early basal insulin treatment in patients insufficiently controlled with metformin is efficient, safe and convenient. Targets for glucose control and HbA1c have to be individualized and the choice of drugs must be risk-adjusted. Risk of hypoglycemia should be used as guide in decision-making for safe treatment of diabetes.
Literatur
Tsujimoto T, Yamamoto-Honda R, Kajio H et al (2014) Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in Type 1 and Type 2 diabetic patients. Diabetes Care 37:217–225
Desouza CV, Bolli GB, Fonseca V (2010) Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33:1389–1394
Graveling AJ, Frier BM (2009) Hypoglycaemia: an overview. Prim Care Diabetes 3:131–139
American Diabetes Association (2013) Standards of medical care in diabetes – 2013. Diabetes Care 36(Suppl 1):S11–S66
Kosiborod M, Inzucchi SE, Goyal A et al (2009) Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 301:1556–1564
McCoy RG, Van Houten HK, Ziegenfuss JY et al (2012) Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35:1897–1901
ORIGIN Trial Investigators, Mellbin LG, Rydén L et al (2013) Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137–3144
Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418
ACCORD Study Group, Gerstein HC, Miller ME et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
Tanenberg RJ, Newton CA, Drake AJ (2010) Confirmation of hypoglycemia in the „dead-in-bed“ syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 16:244–248
Heller SR (2002) Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl 129:27–32
Desouza C, Salazar H, Cheong B et al (2003) Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 26:1485–1489
Stahn A, Pistrosch F, Ganz X et al (2014) Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care 37:516–520
Frier BM, Schernthaner G, Heller SR (2011) Hypoglycemia and cardiovascular risks. Diabetes Care 34(Suppl 2):S132–S137
Amiel SA, Dixon T, Mann R, Jameson K (2008) Hypoglycaemia in Type 2 diabetes. Diabet Med 25:245–254
Fisher BM, Gillen G, Dargie HJ et al (1987) The effects of insulin-induced hypoglycaemia on cardiovascular function in normal man: studies using radionuclide ventriculography. Diabetologia 30:841–845
Marques JL, George E, Peacey SR et al (1997) Altered ventricular repolarization during hypoglycemia in patients with diabetes. Diabet Med 14:648–654
Adler GK, Bonyhay I, Failing H et al (2009) Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 58:360–366
Desouza CV, Bolli GB, Fonseca V (2010) Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33:1389–1394
Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36:1119–1125
Ceriello A (1997) Acute hyperglycaemia and oxidative stress generation. Diabet Med 14(Suppl 3):S45–S49
Huxley RR, Alonso A, Lopez FL et al (2012) Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 98:133–138
Panova EI, Kruglova NE (2008) Factors associated with cardiac arrhythmias in patients with type 2 diabetes mellitus and myocardial infarction. Klin Med (Mosk) 86:23–26
Pochinka I, Strongin L, Struchkova J (2012) Glycaemic variability and ventricular cardiac arrhythmias in type 2 diabetic patients with chronic heart failure. 48th EASD Annual Meeting of the European Association for the Study of Diabetes, Abstr 230. Diabetologia 55(Suppl 1):S102
Lazar HL, McDonnell MM, Chipkin S et al (2011) Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. Ann Surg 254:458–463
Monnier L, Colette C, Owens DR (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2:1094–1100
Gerritsen J, Dekker JM, TenVoorde BJ et al (2001) Impaired autonomic function is ssociated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 24:1793–1798
Heller SR (2008) Hypoglycemia in Type 2 diabetes. Diabetes Res Clin Pract 82(Suppl 2):S108–S111
Wright RJ, Frier BM (2008) Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 24:353–363
Clarke BF, Ewing DJ, Campbell IW (1979) Diabetic autonomic neuropathy. Diabetologia 17:195–212
Psallas M, Tentolouris N, Cokkinos A et al (2006) QT dispersion: comparison between diabetic and non-diabetic individuals and correlation with cardiac autonomic neuropathy. Hellenic J Cardio 47:255–262
Landstedt-Hallin L, Englund A, Adamson U, Lins PE (1999) Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 246:299–307
Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
o A (2013) Executive summary: standards of medical care in diabetes – 2013. Diabetes Care 36(Suppl 1):S4–S10
Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group (2014) Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:39–43
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
Dormandy JA, Charbonnel B, Eckland DJ; PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
ORIGIN Trial Investigators, Mellbin LG, Rydén L et al (2013) Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137–3144
Scirica BM, Bhatt DL, Braunwald E; SAVOR-TIMI 53 Steering Committee and Investigators (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
Chalmers J, Cooper ME (2008) UKPDS and the legacy effect. N Engl J Med 359:1618–1620
Nauck MA (2009) Unraveling the science of incretin biology. Eur J Intern Med 20(Suppl 2):S303–S308
Meier JJ, Schmidt WE, Klein HH (2007) New concepts in the treatment of type 2 diabetes. Internist (Berl) 48:698, 700–707
Garratt KN, Brady PA, Hassinger NL et al (1999) Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119–124
Soydan N, Bretzel RG, Fischer B et al (2013) Reduced capacity of heart rate regulation in response to mild hypoglycemia induced by glibenclamide and physical exercise in type 2 diabetes. Metabolism 62:717–724
Lopez-Liuchi JV, Meier CA (1999) Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study? Eur J Endocrinol 140:4–6
Juurlink DN, Gomes T, Shah BR, Mamdani MM (2012) Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med 29:1524–1528
Mellbin LG, Malmberg K, Norhammar A et al (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54:1308–1317
Matsumoto T, Lopes RA, Taguchi K et al (2014) Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system. Life Sci [Epub ahead of print]
Monnier L, Colette C, Michel F et al (2011) Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes Metab Res Rev 27:348–353
Scognamiglio R, Negut C, Kreutzenberg SV de et al (2006) Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 29:95–100
Engler B, Koehler C, Hoffmann C et al (2011) Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 119:59–61
Hanefeld M, Koehler C, Hoffmann C et al (2010) Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med 27:175–180
Fonseca V, Gill J, Zhou R, Leahy J (2011) An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 13:814–822
Holman RR, Farmer AJ, Davies MJ et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736–1747
Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086
Laubner K, Molz K, Kerner W et al (2013) Daily insulin doses and injection frequencies of Neutral Protamine Hagedorn (NPH) insulin, insulin detemir and glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-Wiss database. Diabetes Metab Res Rev [Epub ahead of print]
Bretzel RG, Nuber U, Landgraf W et al (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073–1084
Janka HU, Plewe G, Riddle MC et al (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254–259
Einhaltung ethischer Richtlinien
Interessenkonflikt. M. Hanefeld, X. Ganz und C. Nolte geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hanefeld, M., Ganz, X. & Nolte, C. Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2. Herz 39, 312–319 (2014). https://doi.org/10.1007/s00059-014-4086-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-014-4086-1